• Earlier in 2026, IDEX Corporation reported stronger-than-expected first-quarter results and lifted its full-year 2026 guidance, citing record orders and raising organic sales growth expectations to 3%–4% alongside an adjusted EPS range of US$8.35 to US$8.55.
• A key insight from this update is the surge in demand within IDEX’s Health & Science Technologies segment, where AI infrastructure, semiconductor, medical, and defense-related markets are emerging as important growth engines.
• We’ll now examine how IDEX’s raised full-year guidance, underpinned by strength in Health & Science Technologies, could influence its investment narrative.

Find 46 companies with promising cash flow potential yet trading below their fair value.

IDEX Investment Narrative Recap

To own IDEX, you need to believe in its ability to compound earnings by supplying mission critical equipment into areas like AI infrastructure, semiconductors, and defense while managing cost inflation and acquisition integration. The Q1 2026 beat and higher full year guidance support the near term earnings catalyst, but do not remove the key risk that demand in cyclical end markets such as chemicals and energy could soften and make results more volatile.

The most relevant recent announcement here is the raised 2026 organic sales growth outlook of 3% to 4% and adjusted EPS guidance of US$8.35 to US$8.55, backed by record orders in Health & Science Technologies. This sits alongside IDEX’s ongoing cost saving initiatives, which, if effective, could help offset tariff related cost pressure and acquisition related margin dilution while the company leans into higher growth, higher complexity applications.

But while guidance has improved, investors should still be aware of...

IDEX's narrative projects $4.2 billion revenue and $697.3 million earnings by 2029.

Uncover how IDEX's forecasts yield a $237.71 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community currently span roughly US$180 to about US$257 per share, reflecting very different expectations for IDEX’s potential. When you weigh those against the improved 2026 guidance supported by Health & Science Technologies demand, it underlines why examining multiple viewpoints on how resilient that growth really is can be important.

Explore 3 other fair value estimates on IDEX - why the stock might be worth as much as 22% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your IDEX research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free IDEX research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IDEX's overall financial health at a glance.

No Opportunity In IDEX?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Capitalize on the AI infrastructure supercycle with our selection of the 46 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.